巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    TScan Therapeutics

    TCRX
    3.150
    0.030
    0.96%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・TScan Therapeutics - 延遲價格・最後更新於 29/06 12:14
    最高位
    3.150
    最低位
    3.030
    開市價
    --
    前收市價
    3.120
    成交量(千)
    0.16
    成交額(百萬)
    0.00
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    75.70
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    11.652 - 1.600
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    TScan Therapeutics
    證券代碼
    TCRX.US
    所屬板塊
    Biotechnology
    公司業務
    TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
    發行量
    23976942
    公司總部
    830 Winter Street
    公司網址
    https://www.tscan.com
    公司電話
    +1 857 399-9500
    暫無內容

    關於

    TScan Therapeutics(TCRX.US)所屬的行業板塊為Biotechnology。
    TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
    詳細公司背景可參考: https://www.tscan.com